Keywords: Japan. XenoPort, Regnite, Horizant, Daiichi Sankyo, Ranmark, Denosumab, Merck & Co, Cancidas, RLS, Bone metastatis, Antifungal

Backing for Japanese approval of Regnite, Ranmark and Cancidas

Article | 05 December 2011

Print This

USA-based XenoPort (Nasdaq: XNPT) saw its shares rise 3% to $4.73 on Friday, when the company said it has received confirmation from ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in